Lightnews — Scholar-powered news

Scribe Therapeutics @scribetx.bsky.social · 1d

Dr. Oakes’ leadership is shaping the future of biotech by pioneering Scribe's validated gene and epigenetic editing technologies, strong pharma collaborations, and pipeline aimed at solving leading killers like heart disease.

Read his BioSpace profile 🔽 www.biospace.com/biospace-40-...

BioSpace 40 Under 40

BioSpace's 40 Under 40 honors 40 exemplary biotech and pharma professionals who have distinguished themselves in their companies and their field. All under the age of 40, these young leaders already d...

www.biospace.com

Scribe Therapeutics @scribetx.bsky.social · 1d

Congrats to our CEO, @benjaminloakes.bsky.social, on being named to BioSpace’s inaugural 40 Under 40 list of exemplary biotech leaders for his vision, innovation, and commitment to advancing next-generation #CRISPR-based therapeutics that improve patient outcomes.

1 1

Scribe Therapeutics @scribetx.bsky.social · 2d

We’re headed to #ESGCT2025 to share our latest #CRISPR #EpigeneticEditing data. Check out our presentation on Thursday, Oct. 9!

🧬 Engineering enhanced epigenetic editors: novel repressor domains drive potent and durable therapeutic gene silencing in non-human primates

Scribe Therapeutics @scribetx.bsky.social · 5d

Meet Scribe at #CGMesa25 in Phoenix 🌵

Our CFO David Parrot will be onsite at the @alliancerm.bsky.social Cell & Gene Meeting on the Mesa to present updates on our work engineering #CRISPR-based medicines for cardiometabolic disease.

Swing by and learn more on Monday, Oct. 6 at 1:45pm MST.

Scribe Therapeutics @scribetx.bsky.social · 9d

We're developing CRISPR-based therapies that address underlying drivers of cardiometabolic disease.

A perfectly good heart ❤️‍🩹 shouldn't be compromised by genetic risk factors. Learn how Scribe is rewriting the future of heart health at scribetx.com

#WorldHeartDay #CRISPR

Scribe

We’re unlocking the future of medicine with CRISPR-based therapeutics that are safe and effective enough to transform everyone's lifetime risk for disease.

scribetx.com

Scribe Therapeutics @scribetx.bsky.social · 9d

When elevated cholesterol and other risk factors run in families, it can feel like your health destiny is already written. But at Scribe, we believe in being fearless 💪 about taking control of your #HeartHealth. ⬇️

1

Scribe Therapeutics @scribetx.bsky.social · 9d

Ahead of #WorldHeartDay, Taylor Swift recently raised an important reminder: heart disease is the leading cause of death, and one person dies from it every 34 seconds.

For some, including her father, a routine stress test revealed severe disease early enough to undergo surgery.

1 1 3

Scribe Therapeutics @scribetx.bsky.social · 12d

Attending the Genome Editing Therapeutics Summit?

Join us Sept. 30 for the opening presentation by Kai-Yuan Chen, Scribe's Director of Data Science & Tech Platform, highlighting DeepXE: our deep learning model powering #CRISPR-CasX therapeutic gRNA design.

#AI #MachineLearning

2

Scribe Therapeutics @scribetx.bsky.social · 13d

An important piece in @forbes.com by Leaps By Bayer highlighting the dangers of high cholesterol, the urgent need for solutions beyond statins, and Scribe’s advances developing #CRISPR gene editing and epigenetic silencing therapies for cardiometabolic disease.

www.forbes.com/sites/juerge...

Treating High Cholesterol Could Become A One-And-Done Treatment

Gene editing and epigenetic silencing offer two ways of changing the basic biology of cholesterol for future treatments beyond statins.

www.forbes.com

1 1

Scribe Therapeutics @scribetx.bsky.social · 15d

This Thursday, join us at the Oppenheimer Private Life Science Company Showcase for a virtual presentation by our CFO David Parrot.

📅 September 25, 2025
🕗 3:15pm ET
📍 Virtual
✅ Register for the event or reach out to our team at www.scribetx.com/contact

Scribe Therapeutics @scribetx.bsky.social · 19d

At Scribe, we’re developing #CRISPR-based genetic medicines safe and potent enough to address high LDL-C, among other drivers of cardiometabolic disease, to improve heart health for all.

Learn more at scribetx.com/pipeline and about #CholesterolEducationMonth from @americanheart.bsky.social

Scribe → Pipeline

scribetx.com

Scribe Therapeutics @scribetx.bsky.social · 19d

Knowing your #cholesterol could save your life. This National #CholesterolEducationMonth, stay up to date on the impact cholesterol levels have on your risk for heart disease. 👇

1

Scribe Therapeutics @scribetx.bsky.social · 22d

Attending the Bank of America Healthcare Trailblazers Private Company Conference in Boston this week?

Book a meeting with Scribe CFO David Parrot to learn about our latest updates, data, and approach to advancing #CRISPR for cardiometabolic disease 👉 www.scribetx.com/contact

Scribe Therapeutics @scribetx.bsky.social · 29d

Check out the data in our latest press release: www.businesswire.com/news/home/20...

Originally presented at #ESCCongress and #CSHL

www.businesswire.com

Scribe Therapeutics @scribetx.bsky.social · 29d

📣 Presenting new breakthrough data from two of our core platforms 📣

We're proud to showcase the success of our Lp(a)-lowering therapy STX-1200 and novel #AI platform, DeepXE, for next-generation #CRISPR-based therapeutics.

More details in our link below 👇

1 1 1

Scribe Therapeutics @scribetx.bsky.social · Sep 8

At Scribe, we run on teamwork and purpose – in and out of the lab.

#JPMCC 2025 marked our 4th year participating in the global J.P. Morgan Corporate Challenge. Check out our reel for highlights our team captured as they ran through San Francisco, repping our “ELXR” tech! 🧪😉

1 1

Scribe Therapeutics @scribetx.bsky.social · Sep 2

If you’ll be in New York for the Cantor Global Healthcare Conference, our CEO @benjaminloakes.bsky.social and CFO David Parrot will be on site and available for one-on-one meetings between Sept. 3-5.

Interested in connecting? Reach out through our website 👉 www.scribetx.com/contact

Scribe Therapeutics @scribetx.bsky.social · Aug 29

Check out our press release for more #ESCCongress presentation details: www.businesswire.com/news/home/20...

@escardio.bsky.social #ESCCongress #WCCardio

www.businesswire.com

Scribe Therapeutics @scribetx.bsky.social · Aug 29

At #ESCCongress for the latest on #CRISPR gene editing treatments for cardiometabolic disease?

On Monday, our CSO Aarif Khakoo will present late-breaking preclinical data on STX-1200, our novel CRISPR-CasX based gene editing therapy to reduce elevated Lp(a) & CVD risk. Read more 👇

1

Scribe Therapeutics @scribetx.bsky.social · Aug 25

🧬 Cell & Gene Meeting on the Mesa #CGMesa25
📅 October 6 at 1:45 PM MST
🗣️ Corporate presentation by CEO @benjaminloakes.bsky.social

Read our full press release: www.businesswire.com/news/home/20...

www.businesswire.com

1

Scribe Therapeutics @scribetx.bsky.social · Aug 25

🧬 Genome Editing Therapeutics Summit
📅 Sept 30 at 8:30 AM ET
🗣️ Kai-Yuan Chen, Director of Data Science and Tech Platform, will open the summit with a presentation on DeepXE, Scribe's deep learning model powering #CRISPR-CasX therapeutic gRNA design.

#AI #MachineLearning

1 1

Scribe Therapeutics @scribetx.bsky.social · Aug 25

Our management team, including CEO @benjaminloakes.bsky.social and CFO David Parrot, will participate and be available for investor meetings.

Cantor Global Healthcare Conference
📅 September 3-5

Bank of America Healthcare Trailblazers Private Company Conference
📅 September 17

1

Scribe Therapeutics @scribetx.bsky.social · Aug 25

🫀 #ESCCongress
📅 Sept 1, between 11:15 AM and 12:00 PM CEST
🗣️ CSO Aarif Khakoo will present “Preclinical proof of concept for STX-1200: potent LPA editing and Apo(a) knockdown via CasX-based gene editing”

@escardio.bsky.social #WCCardio #CRISPR

1

Scribe Therapeutics @scribetx.bsky.social · Aug 25

This fall, we are thrilled to present our latest updates on our #CRISPR genetic and epigenetic editing therapies, new machine learning approach, and corporate strategy at several premier conferences.

If you’ll be at #ECCongress, #CGMesa25, and others, read on for more details 👇

1 1 1

Scribe Therapeutics @scribetx.bsky.social · Aug 22

What does it take to rewrite the story of disease? Our CEO @benjaminloakes.bsky.social‬ shared with @bigthink.com‬ how a mission-driven team like Scribe can redefine what is possible in medicine with #CRISPR.

His insights on leadership, innovation, and bold vision 👇

bigthink.com/business/lea...

Leadership essentials: “Inspire, motivate, and cultivate”

Benjamin Oakes — CEO of therapeutic biotech company Scribe Therapeutics — joins Big Think for a chat about innovation and more.

bigthink.com